Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is male~2. Subject is aged between 18 and 50 years inclusive.~3. Subject has given signed informed consent.~4. Subject's Body Mass Index (BMI) is between 18 and 30 kg/m2 inclusive.~5. Subject weighs less than 100 kg.~6. Subject is considered to be in good health in the opinion of the investigator, as determined by:~   1. A pre-study physical examination with no clinically significant abnormalities.~  2. Vital signs within normal ranges (supine after 3 minutes rest - heart rate: 40 to 80 bpm; systolic BP: 100 to 140 mmHg; diastolic BP: 50-90 mmHg; respiration rate: 8 to 18 breaths per minute; oxygen saturation: 96-100%)~  3. An ECG with no clinically significant abnormalities.~7. Subject's pre-study clinical laboratory findings are within normal range or if outside of the normal range not deemed clinically significant in the opinion of the investigator.~8. Cardiac troponin I is less than the upper limit of the laboratory reference range.~9. A screening echocardiogram demonstrates normal cardiac function, an ejection fraction of between 40% and 70% with no significant valvular regurgitation (grade 1) and/or stenosis and images are deemed to be of good quality by the sonographer.~Exclusion Criteria:~1. Subject has had a clinically significant illness in the four weeks before screening.~2. Use of prescribed mediations in the 3 weeks prior to dosing or over-the-counter preparations (including vitamin supplements and herbal remedies) for 7 days prior to dosing, except paracetamol which will be allowed up to 48 hours prior to dosing.~3. Subject has a significant history of drug/solvent abuse or a positive drugs of abuse test at screening.~4. Subject with a history of alcohol abuse or currently drinks in excess of 28 units per week.~5. Subject smokes more than 5 cigarettes (or equivalent) per day.~6. Subject is not willing to refrain from caffeine/xanthine containing products from 48 hours prior to the screening medical and admission on Day -1 until the post study medical.~7. Subject is in the opinion of the investigator not suitable to participate in the study.~8. Subject who has participated in any clinical study with an investigational drug/device within three months prior to the first day of dosing.~9. Subject who has a positive result of HIV screen, Hepatitis B screen or Hepatitis C screen.~10. Subject has had a serious adverse reaction or significant hypersensitivity to any drug.~11. Subject has donated 500 ml or more of blood within the month prior to screening.~12. Subject has a history of cardiovascular disease or family history of premature cardiovascular disease or death.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Dose-escalation Cohort 1 (Type: EXPERIMENTAL): 4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
- Dose-escalation Cohort 2 (Type: EXPERIMENTAL): 4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
- Dose-escalation Cohort 3 (Type: EXPERIMENTAL): 4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
- Dose-escalation Cohort 4 (Type: EXPERIMENTAL): 4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete